Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.31 |
| ▸ | AHCY | P23526 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19220862 | 1.00 | ADORA3 (0.33) | ADORA3ADORA1TSHRLMNATHRB | |
| SCHEMBL14212364 | 1.00 | ADORA3 (0.33) | ADORA3ADORA1TSHRLMNATHRB | |
| SCHEMBL26444398 | 0.91 | ADORA3 (0.36) | ADORA3ADORA1TSHRLMNATHRB | |
| SCHEMBL23710807 | 0.83 | CA12 (0.33) | — | |
| SCHEMBL19221011 | 0.82 | AKT1 (0.39) | — | |
| SCHEMBL19220861 | 0.82 | AKT1 (0.39) | — | |
| SCHEMBL19220864 | 0.82 | AKT1 (0.39) | — | |
| SCHEMBL11994265 | 0.82 | AKT1 (0.39) | — | |
| SCHEMBL23710806 | 0.82 | AKT1 (0.39) | — | |
| SCHEMBL14212365 | 0.82 | AKT1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239397-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | UNITED STATES GOVERNMENT | 2017-08-24 | — | — | US | disclosed |
| US-20170226232-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226232-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | ALG1, FIBP, COL2A1 | ADORA3 2630/4885ADORA1 2393/4885TSHR 4788/4885 |
| US-20170239397-A1 | MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS | ALG1, FIBP, COL2A1 | ADORA3 2630/4885ADORA1 2393/4885TSHR 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.